

Prof. Dr. Bianca ROCCA

CURRICULUM VITAE and PUBLICATIONS

UPDATED ON 4/11/2021

EDUCATION AND TRAINING

- 23/10/1989 **Medical Degree, Cum Laude** – Catholic University School of Medicine, Rome, Italy.
- 06/1990 First Certificate in English. University of Cambridge (UK).
- 23/10/1995 **PhD. Experimental Oncology.** University of Pisa, Pisa, Italy
- 20/11/1996 **Hematology Fellowship, cum laude.** Catholic University School of Medicine,
- 1995-1998 **Postdoctoral Fellow** – Center for Experimental Therapeutics, Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

PROFESSIONAL EXPERIENCE

- 09/2000-08/2001 **Research Associate**, Research Center of Pathophysiology of Haemostasis, Catholic University, Rome, Italy
- 2001-2004 **Clinical Fellow**, Department of Internal Medicine and Center for Thrombotic and Haemorrhagic Diseases. Catholic University School of Medicine, Rome, Italy.
- 2005-2007 **Adjunct Professor of Pharmacology**, 2nd School of Medicine, ‘La Sapienza’ University, Rome, Italy
- 2007-2016 **Assistant Professor of Pharmacology**, Institute of Pharmacology, Catholic University of Rome, Italy
- 2012-2015 **Board of the PhD program** ‘Pathophysiology and Pharmacology of Haemostasis and Thrombosis’, Catholic University School of Medicine, Rome, Italy
- 2013-2018 **Board of the PhD program** ‘Biomedical Sciences and Public Health’, Catholic University School of Medicine, Rome, Italy
- 2018-present **Board of the PhD program** ‘Experimental and Translational Medicine’ Catholic University School of Medicine, Rome, Italy
- 2016-present **Associate Professor of Pharmacology**, Institute of Pharmacology, Catholic University of Rome, Italy
- 06/2021-present National Scientific Certification (ASN) as **Full Professor in Pharmacology**

INTERNATIONAL APPOINTMENTS, PARTICIPATION TO INTERNATIONAL TASK FORCES AND

GUIDELINES

- 06/2012-2014 *Elected Member of the ‘Nucleus of the Working Group on Thrombosis’ della European Society of Cardiology,*
- 10/2014-2016 *Treasurer*, Working Group of Thrombosis, European Society of Cardiology (<http://www.escardio.org/The-ESC/Communities/Working-Groups/Working-Group->

- on-Thrombosis/About/ Nucleus-2014-2016)
- 09/2015 ‘*Top Italian Scientists*’ (http://www.topitalianscientists.org/top_italian_scientists_VIA-Academy.aspx?Cerca=bianca%20rocca)
- 2016-2017 ***Co-Chair International Task Force*** ESC scientific document ‘Joint consensus document from EHRA/WG Thrombosis, endorsed by HRS, APHRS, Saheart and SOLEACE – on antithrombotic therapy in valvular Atrial Fibrillation’. ESC Working Group on Thrombosis
- 2016-2017 ***Member of the International Task Force*** ‘Antiplatelet drug therapy’. Working Group on Thrombosis, European Society of Cardiology
- 2015 ***Vice-Chairperson*** European Society of Cardiology Working Group on Thrombosis
- 2016-2018 ***Chairperson***, European Society of Cardiology Working Group on Thrombosis (<https://www.escardio.org/Working-groups/Working-Group-on-Thrombosis/nucleus-and-structure>)
- 2017-2018 ***Coordinator of the International Task Force*** for the ESC scientific document ‘Body mass and antithrombotic drugs’ European Society of Cardiology Working Group on Thrombosis.
- 2017-2019 ***Scientific Board of*** Clinical Pharmacology, Italian Society of Pharmacology
- 2017-present ***Scientific Board of*** the ‘Aterosclerosi Trombosi e Biologia Vascolare’ <https://atbv.it/organi-direttivi/>
- 2017-2018 ***Member of the International Task Force of the 2018 ESC guidelines on cardiovascular disease in pregnancy.*** European Society of Cardiology
- 2017-2019 ***Member of the International Task Force of the 2019 ESC guidelines on Diabetes and pre-Diabetes.*** European Society of Cardiology
- 2018-2020 ***Immediate Past-Chairperson***, European Society of Cardiology Working Group on Thrombosis
- 2018-2020 Member of the ***Congress Programme Committee***, European Society of Cardiology
- 2018-2020 ***Ex Officio nucleus Member***, European Society of Cardiology Working Group on Aorta and Peripheral Vascular Disease.
- 2018-2020 ***Co-Chair of the International Task Force***, ESC scientific document for Antithrombotic Therapy in patients with Acute Coronary Syndrome complicated by Cardiogenic Shock or out-of-hospital cardiac arrest, ESC Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association and European Association of Percutaneous Cardiovascular Interventions.
- 2018-present ***Fellow*** of the European Society of Cardiology
- 2020-present ***Ex-Officio Nucleus Member***, European Society of Cardiology Working Group on Thrombosis
- 2020-present Member ***Congress Programme Committee***, European Society of Cardiology

- 2021-present Member *of the International Task Force of the European Hematology Association Guidelines on Management of anti-thrombotic treatment in thrombocytopenic patients* on behalf of the European Society of Cardiology Working Group on Thrombosis
- 2021-present Co-Chair *European Certificate of Advanced Studies in Antithrombotic Management* from the University of Maastricht, The Netherlands (Chair Prof. Hugo Ten Cate).

INTERNATIONAL AND NATIONAL GRANTS

- 2003-2007 FIRB Progetto negoziale: ‘Determinants of the individual responses to COX inhibitors in elderly: new molecular targets’ Funded by the Italian Ministry of University and Research MIUR, cod RBNE01A882_005.
- 2004-2010 ‘Eicosanoids and nitric oxide: mediators of cardiovascular, cerebral and neoplastic diseases (EICOSANOX)’. Frame Program 6 (FP6), grant LSHMCT-2004-005033.
- 2009-2015 ‘Surrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools (SUMMIT)’. Seventh Framework Program, FP7/2007-2013, for the Innovative Medicine Iniziative, grant IMI/115006.
- 2012-2017 ‘Platelet Activation in Type 2 Diabetic Patients with Stable Coronary Artery Disease: Insights into their Thrombotic Propensity using a Genome-Wide Approach’, funded by the Fondazione CARIPO. rif. 2011-0473.
- 2016-2021 ‘New strategies of antiplatelet prophylaxis in essential thrombocythemia: different regimens of low-doses of acetylsalicylic acid’ funded by the Agenzia Italiana del Farmaco (AIFA) Rif. AIFA FARM12Y8H.
- 2018-2023 Aspirin for Cancer Prevention Collaboration (AsCaP). A Study of Platelet Activation and Inhibition in Patients with Colorectal, Breast or Prostate Cancer. Funded by the Cancer Research, UK.
- 2019-2024 ‘Pharmacological Effects of Different Aspirin Dose Regimens’, funded by the British Heart Foundation, funding no. FS/18/49/33752 (PI Prof. Robert Storey, Univ. Of Sheffield)

AWARDS

- 2015-present Scientific Expert for Research and Science, Italian Ministry of the University (MIUR).
- 12/2017 Special note of thanks from the *American Society for Clinical Pharmacology and Therapeutics* for contribution as Reviewer of the ASCPT Journals
- 08/2018 *Certificate of Achievement* in recognition of the outstanding contribution in contribution in serving as *Chairperson of the ESC Working group on Thrombosis*
- 01/2019 *Distinguished Reviewer Award*, European Heart Journal Cardiovascular Pharmacotherapy
- 08/2019 *Certificate of Appreciation* in recognition of the *outstanding contribution to the 2019 ESC Guidelines on diabetes, prediabetes and cardiovascular diseases*, from the ESC

Committee for Practice Guidelines

EDITORIAL BOARDS

- 2010-2012 Editor-in-Chief, 'Frontiers in Pharmacology of Thrombosis'
- 2013-2020 Editorial Board '*Pharmacology Research & Perspectives*'
- 2015-present Editorial Board *European Heart Journal – Cardiovascular Pharmacotherapy* (<http://ehjcvp.oxfordjournals.org>),
- 2018-present Assistant Editor *Diabetes and Vascular Disease Research* (<https://journals.sagepub.com/editorial-board/DVR>)
- 2019-present Advisory Board: *Pharmadvances*. <http://www.pharmadvances.com/organisation>
- 2019-present Review Editor, Editorial Board of Inflammation Pharmacology, specialty section of Frontiers in Immunology and *Frontiers in Pharmacology*.
- 2020-present Associate Editor: *Cardiovascular Drugs and Therapy*, sezione Clinical Pharmacology, <https://www.springer.com/journal/10557/editors>

GRANT REVIEWER

- Grant Reviewer for national Bodies: *University of Messina, Naples and for the , MIUR.*
- Grant Reviewer for national Bodies:
 - University of Oslo (Norway),*
 - University of Leuven (Belgium),*
 - European Society of Cardiology,*
 - The Netherland Organization for Health Research and Development.*

AFFILIATION TO NATIONAL AND INTERNATIONAL SOCIETIES

- 03/2006-present Working Group on Thrombosis, European Society of Cardiology
- 02/2007-present Società Italiana di Farmacologia
- 02/2008-present Working Group of Cardiovascular Pharmacology and Drug Therapy, European Society of Cardiology
- 2017-present Sezione di Farmacologia Clinica, Società Italiana di Farmacologia
- 2021-present Società Italiana Studio Emostasi e Trombosi (SISSET)

INVITED SPEAKER TO NATIONAL AND INTERNATIONAL SCIENTIFIC MEETINGS

Prof. Rocca has been invited as speaker to over 150 national and international scientific meetings

SCIENTIFIC FIELDS OF INTEREST

Main scientific interests are: cardiovascular pharmacology, antithrombotic drugs, eicosanoids, haemostasis, platelets, non-steroidal anti-inflammatory drugs, cardiovascular diseases.

BIBLIOMETRIC INDEXES

Original Articles:	151
H-index Google Scholar:	48
Number of citations (Google Scholar):	13,600

ARTICLES AND REVIEWS ON PUBMED OVER THE PAST 10 YEARS (2010-2021)

1. Tosetto A, **Rocca B**, Petrucci B, Betti S, Soldati D, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli M, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Priolo S, Randi ML, Bertozzi I, Loscocco G, Ricco A, Specchia G, Vannucchi AM, Rodeghiero F, De Stefano V, Patrono C* for the Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators. Association of platelet thromboxane inhibition by low-dose aspirin with platelet count and cytoreductive therapy in essential thrombocythemia. *Clin Pharm Ther*. Epub Ahead of Print. *Rocca B corresponding Author*.

2. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, Savelieva I, Fumagalli S, Bo M, **Rocca B**, Jensen MT, Pierard L, Sudano I, Aboyans V, Asteggiano R. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Acute Cardiovascular Care Association (ACCA), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS) *Eur J Prev Cardiol*. 2021 Epub Ahead of Print

3. Patrono C, **Rocca B**. Aspirin at 120: Retiring, recombining, or repurposing? *Res Pract Thromb Haemost*. 2021;5(4):e12516.

4. Ajjan RA, Kietsiriroje N, Badimon L, Vilahur G, Gorog DA, Angiolillo DJ, Russell DR, **Rocca B**, Storey RF. Antithrombotic therapy in diabetes: which, when, and for how long? *Eur Hear J*. 2021; 42(23):2235-2259.

5. Ten Berg J, Sibbing D, **Rocca B**, Van Belle E, Chevalier B, Collet JP, Dudek D, Gilard M, Gorog DA, Grapsa J, Grove EL, Lancellotti P, Petronio AS, Rubboli A, Torracca L, Vilahur G, Witkowski A, Mehilli J (in stampa). Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. *Eur Hear J*. 2021 42(23):2265-2269.

6. Gorog DA, Price S, Sibbing D, Baumbach A, Capodanno D, Gigante B, Halvorsen S, Huber K, Lettino M, Leonardi S, Morais J, Rubboli A, Siller-Matula JM, Storey RF, Vranckx P, **Rocca B**. Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a Joint Position Paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J Cardiovasc Pharmacother*. 2021;7:125-140.
7. **Rocca B**, Peter K. Platelets, coagulation and the vascular wall The quest to better understand and smarten up our therapeutic targeting of this triad in primary and secondary prevention of cardiovascular events. *Cardiovasc Res*. 2021; 117(9):1998-2000.
8. **Rocca B**, De Cristofaro R. Sirtuin 5, vascular endothelium and fibrinolysis: a deadly embrace? *Cardiovasc Res*. 2021; 117(10):2145-2147.
9. Badimon L, Vilahur G, **Rocca B**, Patrono C. The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis. *Cardiovasc Res*. 2021;117:2001-2015. (BR corresponding Author).
10. Rubboli A, Fresco C, Paciaroni M, **Rocca B**, Pecora D, Enea I, Cuccia C, Patti G (in stampa). How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group. *J Cardiovasc Med*. Epub Ahead of Print.
11. Drew DA, Schuck MM, Magicheva-Gupta MV, Stewart KO, Gilpin KK, Miller P, Parziale MP, Pond EN, Takacs-Nagy O, Zerjav DC, Chin SM, Mackinnon Krems J, Meixell D, Joshi AD, Ma W, Colizzo FP, Carolan PJ, Nishioka NS, Staller K, Richter JM, Khalili H, Gala MK, Garber JJ, Chung DC, Yarze JC, Zukerberg L, Petrucci G, **Rocca B**, Patrono C, Milne GL, Wang M, Chan AT. (2020). Effect of Low-dose and Standard-dose Aspirin on PGE 2 Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial. *Cancer Prevention Res*. 2020;13: 877-888.
12. Parker WAE, Gorog DA, Geisler T, Vilahur G, Sibbing D, **Rocca B**, Storey RF. Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. *Eur Hear J Suppl*. 2020; 22:26-34.
13. **Rocca B**, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiate E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Carpenedo M, Randi ML, Bertozzi I, Paoli C, Specchia G, Ricco A, Vannucchi AM, Rodeghiero F, Patrono C, De Stefano V. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia *Blood*. 2020;136(2):171-182.
14. Sacco M, Ranalli P, Lancellotti S, Petrucci G, Dragani A, **Rocca B** and De Cristofaro R. Increased Von Willebrand Factor levels in Polycythemia Vera and phenotypic differences with Essential Thrombocythemia. *Res Pract Thromb Haemost*. (Rocca B corresponding Author). 2020; 4:413-421.
15. Walker J, Cattaneo M, Badimon L, Agnelli G, Chan AT, Lanasa A, **Rocca B**, Rothwell P, Patrignani P, Langley R, Vilahur G, Cosentino F (2020). Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. *Ecancermedicalscience*, ISSN: 1754-6605.
16. Santilli F, Zaccardi F, Liani R, Petrucci G, Simeone P, Pitocco D, Tripaldi R, Rizzi A, Formoso G, Pontecorvi A, Angelucci E, Pagliaccia F, Golato M, De Leva F, Vitacolonna E, **Rocca B**, Consoli A, Patrono C. In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. *Diabetes Metab Res Rev*. 2020;36:e3232.

17. **Rocca B**, Patrono C. Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. *Diab Res Clin Pract*, 2020;160: 108008,
18. Rubboli A, Barbaresi E, **Rocca B**. From the Choice of a Regimen to the Choice of an Intensity: Changing Perspective in the Antithrombotic Therapy of Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. 2019, *Cardiovasc Drugs Ther*. 34:143-144.
19. **Rocca B**, Rubboli A, Zaccardi F. Antithrombotic therapy and revascularisation strategies in people with diabetes and coronary artery disease. *Eur J Prev Cardiol*. 2019;26 (2_suppl):92-105.
20. Patrono C, **Rocca B**. Measurement of Thromboxane Biosynthesis in Health and Disease. *Front Pharmacol*. 2019;10.
21. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, **Rocca B**, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2020;41(2):255-323.
22. Petrucci G, Zaccardi F, Giarretta A, Cavalca V, Capristo E, Cardillo C, Pitocco D, Porro B, Schinzari F, Toffolo G, Tremoli E, **Rocca B**. Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation. *J Thromb Haemost*. 2019;17(6):885-895.
23. Parker WAE, Orme RC, Hanson J, Stokes HM, Bridge CM, Shaw PA, Sumaya W, Thorneycroft K, Petrucci G, Porro B, Judge HM, Ajjan RA, **Rocca B**, Storey RF. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. *Platelets*. 2019;13:1-10.
24. Porro B, Di Minno A, **Rocca B**, Fiorelli S, Eligini S, Turnu L, Barbieri S, Parolari A, Tremoli E, Cavalca V. Characterization of aspirin esterase activity in health and disease: In vitro and ex vivo studies. *Biochem Pharmacol*. 2019;163:119-127.
25. Habib A, Petrucci G, **Rocca B**. Pathophysiology of Thrombosis in Peripheral Artery Disease. *Curr Vasc Pharmacol*. 2020;18(3):204-214.
26. Pozzoli G, Marei HE, Althani A, Boninsegna A, Casalbore P, Marlier LN, Lanzilli G, Zonfrillo M, Petrucci G, **Rocca B**, Navarra P, Sgambato A, Cenciarelli C. Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation. *J Cell Physiol*. 2019 Jan 30
27. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, Valgimigli M, Huber K; Potpara T, Blomström Lundqvist C, Crijns H, Steffel J, Heidbüchel H, Stankovic G, Airaksinen J, Ten Berg JM, Capodanno D, James S, Bueno H, Morais J, Sibbing D, **Rocca B**, Hsieh MH, Akoum N, Lockwood DJ, Gomez Flores JR, Jardine R. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). *Europace*. 2018 21(2):192-193.
28. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA; Deaton C, Simpson IA, Aboyans V, Agewall S, Barbato E, Calda P, Coca A, Coman IM, De Backer J, Delgado V, Di Salvo

G, Fitzsimmons S, Fitzsimons D, Garbi M, Gevaert S, Hindricks G, Jondeau G, Kluin J, Lionis C, McDonagh TA, Meier P, Moons P, Pantazis A, Piepoli MF, **Rocca B**, Roffi M, Rosenkranz S, Sarkozy A, Shlyakhto E, Silversides CK, Sliwa K, Sousa-Uva M, Tamargo J, Thorne S, Van de Velde M, Williams B, Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Jung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Zamorano JL, Hammoudi N, Piruzyan A, Mascherbauer J, Samadov F, Prystrom A, Pasquet A, Caluk J, Gotcheva N, Skoric B, Heracleous H, Vejlstrup N, Maser M, Kaaja RJ, Srbinovska-Kostovska E, Mounier-Vehier C, Vakhtangadze T, Rybak K, Giannakoulas G, Kiss RG, Thrainsdottir IS, Erwin RJ, Porter A, Geraci G, Ibrahimi P, Lunegova O, Mintale I, Kadri Z, Benlamin H, Barysiene J, Banu CA, Caruana M, Gratii C, Haddour L, Bouma BJ, Estensen ME, Hoffman P, Petris AO, Moiseeva O, Bertelli L, Tesic BV, Dubrava J, Koželj M, Prieto-Arévalo R, Furenäs E, Schwerzmann M, Mourali MS, Ozer N, Mitchenko O, Nelson-Piercy C. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J*. 2018;39(34):3165-3241.

29. De Stefano V, **Rocca B**, Tosetto A, Soldati D, Petrucci G, Beggiato E, Bertozzi I, Betti S, Carli G, Carpenedo M, Cattaneo D, Cavalca V, Dragani A, Elli E, Finazzi G, Iurlo A, Lanzarone G, Lissandrini L, Palandri F, Paoli C, Rambaldi A, Ranalli P, Randi ML, Ricco A, Rossi E, Ruggeri M, Specchia G, Timillero A, Turnu L, Vianelli N, Vannucchi AM, Rodeghiero F, Patrono C. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design - implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. 2018 *Blood Cancer Journal*. 8(6):49. De Stefano V and **Rocca B** co-first Authors

30. **Rocca B**, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet JP, Grove EL, Halvorsen S, Huber K, Morais J, Patrono C, Rubboli A, Seljeflot I, Sibbing D, Siegbahn A, Ten Berg J, Vilahur G, Verheugt FWA, Wallentin L, Weiss TW, Wojta J, Storey RF. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. *Eur Heart J*. 2018;39(19):1672-1686.

31. Spinthakis N, Farag M, **Rocca B**, Gorog DA. More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. *J Am Heart Assoc*. 2018 ;7(3). pii: e007754. doi: 10.1161/JAHA.117.007754.

32. Walker J, Hutchison P, Ge J, Zhao D, Wang Y, Rothwell PM, Gaziano JM, Chan A, Burn J, Chia J, Langley R, O'Donnell V, **Rocca B**, Hawkey C. Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin. *Ecancermedicalscience*. 2018; 12:813. doi: 10.3332/ecancer.2018.813.

33. Borst O, Munzer P, Alnaggar N, Geue s, Tegtmeier r, Rath d, Droppa m, Seizer P, Heitmeier S, Heemskerk JWM, Jennings LK, Storey RF, Angiolillo DJ, **Rocca B**, Spronk H, Ten Cate H, Gawaz M, Geisler T. Inhibitory mechanisms of very low dose rivaroxaban in non-ST-elevation myocardial infarction. *Blood Adv*, ISSN: 2473-9537. 2018; 2(6):715-730

34. van Zuydam NR, Ahlqvist E, Sandholm N, Deshmukh H, Rayner NW, Abdalla M, Ladenvall C, Ziemek D, Fauman E, Robertson NR, McKeigue PM, Valo E, Forsblom C, Harjutsalo V; Finnish Diabetic Nephropathy Study (FinnDiane), Perna A, Rurali E, Marcovecchio ML, Igo RP Jr, Salem RM, Perico N, Lajer M, Käräjämäki A, Imamura M, Kubo M, Takahashi A, Sim X, Liu J, van Dam RM, Jiang G, Tam CHT, Luk AOY, Lee HM, Lim CKP, Szeto CC, So WY, Chan JCN; Hong Kong Diabetes Registry Theme-based Research Scheme Project Group, Ang SF, Dorajoo R, Wang L, Clara TSH, McKnight AJ, Duffy S; Warren 3 and Genetics of Kidneys in Diabetes (GoKinD) Study Group, Pezzolesi MG; GENIE (GENetics of Nephropathy an International Effort) Consortium, Marre M,

Gyorgy B, Hadjadj S, Hiraki LT; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group, Ahluwalia TS, Almgren P, Schulz CA, Orho-Melander M, Linneberg A, Christensen C, Witte DR, Grarup N, Brandslund I, Melander O, Paterson AD, Tregouet D, Maxwell AP, Lim SC, Ma RCW, Tai ES, Maeda S, Lyssenko V, Tuomi T, Krolewski AS, Rich SS, Hirschhorn JN, Florez JC, Dunger D, Pedersen O, Hansen T, Rossing P, Remuzzi G; SURrogate markers for Micro- and Macrovascular hard endpoints for Innovative diabetes Tools (SUMMIT) Consortium, Brosnan MJ, Palmer CNA, Groop PH, Colhoun HM, Groop LC, McCarthy MI. A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. *Diabetes*. 2018;67(7):1414-1427. (BR part of the SUMMIT Consortium)

35. Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, **Rocca B**, Siegbahn A, Storey R, Vilahur G. Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. *J Am Coll Cardiol*. 2017 70(14):1760-1776.

36. Lip GL, Fauchier L, De Caterina R, Lane DA, Larsen TB, Marin F, Potpara T, Sarrafzadegan N, Collet JP, Morais J, Vilahur G, Weiss TW, Olshansky B, Narasimhan C, Varela G, Sliwa K, Pierard LA, Boriani G and **Rocca B**. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRs), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). *Europace*. 2017 19(11):1757-1758.

37. Lip GL, Fauchier L, De Caterina R, Lane DA, Larsen TB, Marin F, Potpara T, Sarrafzadegan N, Collet JP, Morais J, Vilahur G, Weiss TW, Olshansky B, Narasimhan C, Varela G, Sliwa K, Pierard LA, Boriani G and Rocca B. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRs), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). *Thromb Haemost*. 117(12):2215-2236, 2017

38. Zaccardi F, **Rocca B**, Rizzi A, Ciminello A, Teofili L, Ghirlanda G, De Stefano V, Pitocco D. Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: a case-control study. *Nutr Metab Cardiovasc Dis*. 2017 27(10):902-909.

39. Giarretta A, **Rocca B**, Di Camillo B, Toffolo G and Patrono C. In silico modeling of the antiplatelet pharmacodynamics of low-dose aspirin in health and disease. *Clin Pharmacol Ther*. 2017. 102(5):823-831.

40. Cavalca V, **Rocca B**, Veglia F, Petrucci G, Porro B, Myasoedova V, De Cristofaro R, Turnu L, Bonomi A, Songia P, Cavallotti L, Zanobini M, Camera M, Alamanni F, Parolari A, Patrono C, Tremoli E. On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens (*corresponding Author*). *Clin Pharmacol Ther*. 2017. doi: 10.1002/cpt.702. 102(5):849-858.

41. Patrono C, **Rocca B**. Type 2 Diabetes, Obesity, and Aspirin Responsiveness. *J Am Coll Cardiol*. 2017 2017;69(6):613-615.

42. Halvorsen S, Storey RF, **Rocca B**, Sibbing D, Ten Berg J, Grove EL, Weiss TW, Collet JP, Andreotti F, Gulba DC, Lip GY, Husted S, Vilahur G, Morais J, Verheugt FW, Lanan A, Al-Shahi

- Salman R, Steg PG, Huber K; ESC Working Group on Thrombosis. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. *Eur Heart J*. 2017. 38(19):1455-1462. doi: 10.1002/cpt.694.
43. Russo NW, Petrucci G, **Rocca B**. Aspirin, stroke and drug-drug interactions. *Vasc Pharmacol*. 2016;87:14-22.
44. Petrucci G, Rizzi A, Cavalca V, Habib A, Pitocco D, Veglia F, Ranalli P, Zaccardi F, Pagliaccia F, Tremoli E, Patrono C, **Rocca B**. Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. *Thromb Haemost*. 2016;116(5):891-896.
45. **Rocca B**, Husted S. Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes. *Drugs & Aging*. 2016. 33(4):233-48
46. Zaccardi F, Rizzi A, Petrucci G, Ciaffardini F, Tanese L, Pagliaccia F, Cavalca V, Ciminello A, Habib A, Rizzo P, Squellerio I, Tremoli E, **Rocca B**, Pitocco D and Patrono C. In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus. *Diabetes*. 2016; 65 (2):503-509. *Rocca B corresponding Author*.
47. Andreotti F, **Rocca B**, Husted S, Ramzi A, ten Berg J, Cattaneo M, Collet JP, De Caterina R, Fox KAA, Halvorsen S, Huber K, Hylek EM, Lip G, Montalescot G, Morais J, Patrono C, Verheugt FWA, Wallentin L, Weiss TW, Storey RF on behalf of the ESC Thrombosis Working Group. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. *Eur Heart Jour*. 2015;36(46):3238-49
48. **Rocca B** and Patrono C. Platelet progenitors: the hidden drug target. *Eur Heart Jour*. 2015;36(45):3211-3.
49. Barbieri S, Petrucci G, Amadio P, Tarantino E, Pesce M, Machlus KR, Ranelletti FO, Granellini S, **Rocca B**, Weksler BB, Italiano JE Jr, Tremoli E. Abnormal Megakaryopoiesis and Platelet Function in Cyclooxygenase-2-Deficient Mice. *Thromb Haemost*. 2015; 114(6):1218-29.
50. Lancellotti S, Dragani A, Ranalli P, Petrucci G, Basso M, Tartaglione R, **Rocca B** and De Cristofaro R. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. *J Thromb Haemost*..2015;13(7):1226-37 (*BR corresponding Author*).
51. Zaccardi F, **Rocca B**, Pitocco D, Tanese L, Rizzi A, Ghirlanda G. Mean Platelet Volume, Platelet Distribution Width, and Platelet Count in Type 2 Diabetes Mellitus, Impaired Fasting Glucose, and Metabolic Syndrome: systematic review and meta-analysis. *Diab/Metab Res Rev*. 2015, 31(4):402-10. doi: 10.1002/dmrr.2625.
52. Cavalca V*, **Rocca B***, Squellerio I, Dragani A, Veglia F, Pagliaccia F, Porro B, Barbieri S, Tremoli E and Patrono C. In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythemia. *Thromb Haemost*. 2014; 112(1):118-27 (**CV and RB equal Contributors*)
53. Pagliaccia F, Habib A, Pitocco D, Petrucci G, Zaccardi F, di Stasio E, **Rocca B**. Stability of urinary thromboxane A2 metabolites and adaptation of the extraction method to small urine volume. *Clin Lab*. 2014; 60(1):105-11.
54. Patrono C, **Rocca B**, De Stefano V. Platelet Activation and Inhibition in Polycythemia Vera and Essential Thrombocythemia. *Blood*. 2013;121(10):1701-11.
55. **Rocca B**, Dragani A, Pagliaccia F. Tailoring aspirin therapy. *Expert Rev Cardiovasc Ther*. 2013; 11(3):365-79.
56. Pitocco D, Zaccardi F, Tarzia P, Milo M, Scavone G, Rizzo P, Pagliaccia F, Nerla R, Di

Franco A, Manto A, **Rocca B**, Lanza GA, Crea F, Ghirlanda G. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. *Diab Obes Metab*. 2013; 15(5):427-31.

57. **Rocca B**, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Cardillo C, Morsetti R, Mirabella M, Ghirlanda G, Davi G, Patrono C. The Recovery of Platelet Cyclooxygenase Activity Explains Interindividual Variability in Responsiveness to Low-Dose Aspirin in Patients With and Without Diabetes. *J Thromb Haemost*. 2012; 10(7):1220-30.

58. Patrono C, **Rocca B**. Aspirin and Other COX-1 Inhibitors. *Handb Exp Pharmacol*. 2012;(210):137-64.

59. Patrono C, **Rocca B**. Interindividual variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of evidence. *Dialogues Cardiovasc Med*, 2011;16:5-20.

60. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, **Rocca B**, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. *Blood*. 2012;119(15):3595-603. (*Rocca B corresponding Author*)

61. **Rocca B**, Petrucci G. Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms. *Thrombosis*, 2012;2012:376721.

62. Framarino Dei Malatesta M, Corona LE, De Luca L, **Rocca B**, Manzia TM, Orlando G, Tisone G, Iaria G. Successful pregnancy in a living-related kidney transplant recipient who received sirolimus throughout the whole gestation. *Transplantation*. 2011;91(9):e69-71.

63. Cesario A, **Rocca B**, Rutella S. The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer. *Curr Medicin Chem*. 2011. 18:2263-71.

64. Simeoni S, Biselli R, D'Amelio R, **Rocca B**, Lattanzio S, Mucci L, Davi G, Patacchioli FR. Stress-induced salivary cortisol secretion during hypobaric hypoxia challenge and in vivo urinary thromboxane production in healthy male subjects. *Stress* 2011;14:282-9.

65. Patrono C, **Rocca B**. Interindividual variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of evidence. *Dialogues in Cardiovascular Medicine*, 2011;16:5-20

66. Petrucci G, De Cristofaro R, Rutella S, Ranelletti FO, Pocaterra D, Lancellotti S, Habib A, Patrono C, **Rocca B**. Prostaglandin E2 differentially modulates human platelet function through the EP2 and EP3 receptors. *J Pharmacol Exp Ther* 2011;336(2):391-402.

67. Mattoscio D, Evangelista V, De Cristofaro R, Recchiuti A, Pandolci A, Di Silvestre S, Manarini S, Martelli N, **Rocca B**, Petrucci G, Angelici D, Battistini L, Robuffo I, Pensabene T, Pieroni L, Furnari M, Pardo F, Quattrucci S, Lancellotti S, Davi G, Romano M. Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. *FASEB J* 2010;24(10):3970-80.

68. Arcangeli A, **Rocca B**, Salvatori G, Ciancia M, De Cristofaro R, Antonelli M. Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: Effects on platelet function in the systemic circulation and across the filter. *Thromb Res*. 2010;126(1):24-31.

69. Patrono C, **Rocca B**. The future of antiplatelet therapy in cardiovascular disease. *Annu Rev Med*. 2010; 61:49-61.

70. **Rocca B**, Petrucci G. Personalized Medicine, pharmacogenetics and clopidogrel: unraveling variability of response. *Mol Interv* 2010; 10:12-19.

71. Lancellotti S, De Filippis V, Pozzi N, Peyvandi F, Palla R, **Rocca B**, Rutella S, Pitocco D,

Mannucci PM, De Cristofaro R. Formation of Methionine-sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13. A new prothrombotic mechanism in diseases associated with oxidative stress. *Free Radic Biol Med.* 2010; 48:446-56.

72. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, Mucci L, Ferrante E, Habib A, Ranelletti FO, Ciabattoni G, Davi G, Patrono C, **Rocca B.** The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. *Blood.* 2010; 115:1054-61.

73. Dragani A, Brancati F, Pascale S, Mattoscio D, **Rocca B.** Clinical and laboratory phenotype associated with the aspirin-like defect. *Br J Haematol.* 2010,148:659–669.